## FORM 4

## UNIT

Washington, D.C. 20549

	ED	STATES	<b>SECURITIES</b>	AND EXCH	ANGE (	COMMISSI	ON
--	----	--------	-------------------	----------	--------	----------	----

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average to	ourden						
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Rule 10b5-1(c). See Instruction 10.																	
Name and Address of Reporting Person*     Ho William Tai-Wei				2. Issuer Name <b>and</b> Ticker or Trading Symbol IN8BIO, INC. [ INAB ]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)    Director   10% Owner   Other (specify)			mer			
(Last) (First) (Middle) C/O IN8BIO, INC. 350 5TH AVE. SUITE 5330				3. Date of Earliest Transaction (Month/Day/Year) 10/04/2024								Officer (give title Other (specify below)  PRESIDENT AND CEO					
(Street) NEW YORK NY 10118				Line)  Form filed by One Report								ing Person					
(S	State)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				Execution Date,							Beneficially Owned Followi		Form: I (D) or I	Direct Ir Indirect B tr. 4) C	7. Nature of ndirect Beneficial Ownership		
								v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock			10/04/2	4/2024			A		126,582	2 A	(1)	2,548,094		94 D			
Common Stock												72,999		I		By child	
Common Stock											73,000		I B		By child		
Common Stock												36,5	00			See Sootnote <sup>(2)</sup>	
Common Stock										36,500		1 1 1 1 1		See ootnote <sup>(2)</sup>			
Common Stock											36,500				See cootnote <sup>(2)</sup>		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	Code		Derivativ Securitie Acquired Disposed	ve es d (A) or d of (D)	Expiration Date of Securit (Month/Day/Year) Underlyin Derivative		es Security	8. Price of Derivative Security (Instr. 5)	e derivativ Securiti Benefici Owned Followir	ve Owner es Form: ially Direct or Indi ng (I) (Ins	Ownership Form: Direct (D) or Indirect	Beneficial Ownership ect (Instr. 4)			
			Code	v	(A)	(D)	Date Exercisa	able	Expiration Date		or Number		Transac	tion(s)			
\$1.25	10/04/2024		D <sup>(3)</sup>			81,967	(4)		06/13/2025	Common Stock	81,967	(3)(5)	0		D		
\$0.45	10/04/2024		A <sup>(3)</sup>		81,967		(4)		10/04/2025	Common Stock	81,967	967 (3)(5) 81,90		067	D		
\$0.27	10/04/2024		A		126,582		(4)		10/04/2027	Common Stock	126,582	(1)	126,	582	D		
	Iliam Tai-  (F BIO, INC. AVE. SUIT  ORK N (S Security (Inst Stock	(First) BIO, INC. AVE. SUITE 5330  ORK NY  (State)  Tolerance of Conversion of Exercise Price of Derivative Security  \$1.25	(First)	Code   Stock   Stock	Iliam Tai-Wei	Institute	Inam Tai-Wei	INSBIO, INC.   INAB	INSBIO, INC.   INAB	INSBIO, INC.   INAB     INSBIO, INC.   INAB     INSBIO, INC.   INAB     INSBIO, INC.   INAB   INSBIO, INC.   INSBIO,	INSBIO, INC.   INAB	INSBIC, INC. [INAB ]	INSBIO, INC.   INAB	INSBIO_, INC.   INAB	INSBIO_INC.   INAB	INSBIO_INC_ (First)	

- 1. The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for \$0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock.
- 2. The shares are held by a relative of the Reporting Person. The Reporting Person has voting power pursuant to a voting proxy.
- 3. The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of \$1.25 and expiration date of June 13, 2025. The exercise price was reduced to \$0.45 and the warrant expiration date was extended to October 4, 2025.
- 5. The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for \$1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

/s/ Jason Minio, Attorney-in-

10/08/2024

Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.